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Abstract
The cancer stem cell hypothesis suggests that tumors contain a small population of cancer cells that have the ability to
undergo symmetric self-renewing cell division. In tumors that follow this model, cancer stem cells produce various kinds of
specified precursors that divide a limited number of times before terminally differentiating or undergoing apoptosis. As cells
within the tumor mature, they become progressively more restricted in the cell types to which they can give rise. However,
in some tumor types, the presence of certain extra- or intracellular signals can induce committed cancer progenitors to
revert to a multipotential cancer stem cell state. In this paper, we design a novel mathematical model to investigate the
dynamics of tumor progression in such situations, and study the implications of a reversible cancer stem cell phenotype for
therapeutic interventions. We find that higher levels of dedifferentiation substantially reduce the effectiveness of therapy
directed at cancer stem cells by leading to higher rates of resistance. We conclude that plasticity of the cancer stem cell
phenotype is an important determinant of the prognosis of tumors. This model represents the first mathematical
investigation of this tumor trait and contributes to a quantitative understanding of cancer.
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Introduction
Traditionally, many different cell types within a tumor have
been considered to have tumorigenic potential and possess the
ability to cause cancers in secondary recipients. By contrast, the
cancer stem cell hypothesis suggests that only a small subpopu-
lation of tumor cells has that potential [1]. This hypothesis has
been shown consistent with data from such diverse cancer types as
chronic and acute myeloid leukemias [2,3], breast cancer [4],
colorectal cancer [5], mesenchymal neoplasms [6], head and neck
squamous cell carcinoma [7], and pancreatic cancer [8]. The
investigation of cancer stem cells in melanoma, however, has led to
controversial findings. Some studies suggested that melanoma cells
that are capable of transplanting the disease are exceedingly rare
[9] while others, using more severely immunocompromised mice,
found that cells with those capabilities are very common within the
tumor [10]. Similarly, the frequency of tumor cells positive for
stem cell-like markers in breast cancer varies according to the stage
and subtype of the tumor [11].
These findings have led to discussions about the applicability of
the cancer stem cell hypothesis to all tumor types, and also the
ability of xenotransplantation assays to reliably identify cancer
stem cells [12,13]. The differential ability of mouse models to
detect cancer stem cells may be explained by a context-dependent
phenotype of those cells, as supported by evidence from co-
injection experiments of stromal and cancer cells [10]. In these
studies, the efficiency of transplantation of putative cancer stem
cells was higher when stromal cells were co-injected as compared
to injection of cancer stem cells alone. This data suggests that the
ability of cells to initiate neoplastic growth may not only depend on
the severity of immunodeficiency of assay mice, but also on the
microenvironmental context of these cells [14].
The phenotypic plasticity of stem cells has been a topic
attracting great interest. Studies of cells in the central nervous
system, for instance, have shown that certain extracellular signals
can induce oligodendrocyte precursor cells to dedifferentiate into
multipotential neural stem cells [15]. These extracellular signals
are provided through exposure to fetal calf serum and certain
cytokines, including some bone morphogenic proteins, as well as
basic fibroblast growth factor (bFGF), and cause many purified
oligodendrocyte precursors to revert to a state that resembles that
of multipotential neural stem cells [15]. Similarly, a study in which
mature astrocytes were exposed to transforming growth factor a
(TGFa) demonstrated that a single extracellular factor is sufficient
to induce differentiated cells of the central nervous system to
regress into a stem-like cell stage [16]. This observed plasticity of
normal tissue stem cells has implications for tissue organization in
general, and the view of rigid differentiation hierarchies of cells
must be revised in light of these findings.
Observations parallel to those observing a dedifferentiation
potential of normal cells have also been made with regard to
cancer cells. A recent study identified signaling within the
perivascular niche as a driving force for tumor cells to acquire
stem cell characteristics. In this study, nitric oxide was shown to
activate Notch signaling via cGMP and PKG in a subset of glioma
cells resulting in acquisition of the side population phenotype and
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ations occurred within as little as two hours of treatment and had
long-term effects on the phenotype generally associated with stem
cell character. This plasticity of tumor stem cells may also apply to
liquid tumors, as it was recently shown that leukemia-initiating
cells in AML patients harboring mutations in nucleophosmin
(NPM) can reside in the CD34+ as well as CD34- fraction [18].
The ability of committed cancer progenitors to dedifferentiate
to a stem-like state has important implications for the dynamics of
tumor progression and the response to therapy. In this paper, we
design a novel mathematical model to quantify the effects of the
dedifferentiation rate on disease outcome. As all mathematical
modeling approaches, our framework represents an abstraction of
the biological system and as such should be considered as a toy
model to investigate several characteristics of the system. This
work is part of a growing literature describing mathematical
investigations of cancer stem cells [19,20,21,22,23,24].
Methods
vWe designed a simple mathematical model to investigate the
dynamics of different cell populations during tumor progression and
treatment. The model considers three differentiation stages for both
the healthy and the cancer cell differentiation hierarchies. Stem cells
reside at the top of the hierarchy and give rise to progenitor cells,
which in turn give rise to differentiated cells (Fig. 1). Denote the
abundances of healthy stem, progenitor, and differentiated cells by
x0, x1,a n dx2, respectively, and the abundances of the corresponding
cancer cell types by y0, y1,a n dy2. Healthy stem cells proliferate at
raterxanddieatrated0,andgiverisetohealthyprogenitorsatrateax
per day; the rate ax also includes the possibility of limited expansion
in the progenitor compartment via symmetric self-renewing
progenitor cell divisions. Progenitors die at rate d1 and give rise to
healthy differentiated cells at rate bx per day; the latter cells die at
rate d2. Similarly, cancer stem cells proliferate at rate ry and give rise
to cancer progenitors at rate ay, which in turn give rise to
differentiated cancer cells at rate by per day. Again, the rate by
includes the possibility of differentiated cell replication. The death
rates per day of the cancer cell types are denoted by c0, c1,a n dc2.I n
the simplest form of our model, we consider these parameters to be
constant unless external factors – such as the administration of
treatment–areappliedtothesystem.However,themodelcaneasily
be extended to include more complex scenarios such as variability in
the microenvironment, involvement of the immune system, and
interactions between cancer and stromal cells. Such situations may
be described by considering a distribution of parameters from which
the values are selected. In the absence of estimates for the
parameters and their distributions, however, we chose to analyze
the model in its simpler form of constant parameter values.
In addition to their ability to produce differentiated cancer cells,
cancer progenitors may regress to a stem-like state via genetic,
epigenetic, or other mechanisms [17]. The rate at which cancer
progenitors dedifferentiate per day is denoted by c. This rate may
be a function of the microenvironmental conditions of these cells
and can also vary over time as tumors become more aggressive.
There may also be a similar propensity of healthy progenitor cells
to regress to a stem cell like state [15,16]; a rate of dedifferentiation
of healthy progenitors can be included in the model but is
neglected for purposes of clarity. We consider the production of
stem cells to be limited by the density of both healthy and cancer
stem cells; this modeling assumption is made because stem cell
numbers are limited by the availability of extracellular resources as
well as spatial constraints within the tissue, and therefore the
production of stem cells is constrained by those resources and
spatial considerations regardless of whether they are produced by
symmetric division or dedifferentiation. The density dependence is
achieved by the functions wx~1{ x0zvy0 ðÞ =kxand wy~1{
x0zy0 ðÞ =ky for these two cell types. The terms kx and ky represent
the carrying capacity that the healthy and cancer stem cells may
expand to, and the term v represents the increased crowding that
cancer cells can tolerate. It is for this density dependence effect
that we include the healthy differentiation hierarchy in our system.
Note that the parameters kx and ky can be scaled to describe
situations with extensive competition between cells (large extent of
density dependence) as well as situations with little competition.
Then the basic mathematical model is given by
_ x x0~ rxqx{d0 ðÞ x0
_ y y0~ ryqy{c0
  
y0zcqyy1
_ x x1~axx0{d1x1
_ y y1~ayy0{c1y1{cqyy1
_ x x2~bxx1{d2x2
_ y y2~byy1{c2y2
ð1Þ
For shorthand we will write _ x x~fx x ðÞand _ y y~fy y ðÞinstead of
equation (1). In order to study the dynamics of these cells in
response to therapy, we denote the rates of production of cancer
cells during treatment by ~ r ryƒry, ~ a ayƒay, and ~ b byƒby. We may
also investigate an additional or alternative effect of therapy on the
death rates of cancer cells, leading to increased rates during
treatment: ~ c c0§c0, ~ c c1§c1, and ~ c c2§c2. Note that we do not allow
the terminally differentiated cells to dedifferentiate to give rise to
progenitors; this modeling assumption is made since in most tumor
types, terminally differentiated cancer cells are post-mitotic and
therefore incapable of dedifferentiating.
The model outlined above considers the dynamics of treatment
response without the possibility of acquired resistance. Even drugs
that elicit a dramatic initial response often fail later on due to the
emergence of resistance mutations which render the drug
ineffective. Two prominent examples are the point mutations in
BCR-ABL and EGFR that confer resistance against the small
molecule inhibitors imatinib/dasatinib and erlotinib/gefitinib
[25,26]. In the context of our model, the first cell carrying a
resistance mutation can only initiate a long-lived clone if it is a
stem cell, or alternatively a progenitor that dedifferentiates to a
stem-like state. Denote the rate at which a resistance mutation
arises per cell division by u. The probability of resistance depends
on the total number of stem cell divisions and a fraction of
progenitor cell divisions, given by
Rt ðÞ ~
ð t
0
~ r ryy0 s ðÞ zcy1 s ðÞ
  
ds
Note that a resistant cell can arise during a division of a sensitive
cancer stem cell or during a dedifferentiation event of a sensitive
cancer progenitor cell. Then the probability that at least one
resistant cell that will persist in the population has arisen by time t
is given by Pt ðÞ ~1{exp {uR t ðÞ ½  .
Furthermore, the basic mathematical model as given by
equation (1) can be expended to include a differentiation hierarchy
of drug-resistant cancer cells. Denote the abundance of resistant
stem, progenitor and differentiated cancer cells by z0, z1 and z2,
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cells is given by
_ x x0~(rxwx{d0)x0
_ y y0~ ry 1{u ðÞ wy{c0
  
y0zcwyy1
_ z z0~ryuwyy0z rzwz{c0 ðÞ z0zcwzz1
_ x x1~axx0{d1x1
_ y y1~ayy0{c1y1{cwyy1
_ z z1~azz0{c1z1{cwzz1
_ x x2~bxx1{d2x2
_ y y2~byy1{c2y2
_ z z2~bzz1{c2z2
ð2Þ
Here the growth, death and differentiation rates of resistant cancer
cells are denoted by the parameters ry, az,b z, and c0,c 1, and c2,
respectively.
Results
Let us first discuss the effects of the dedifferentiation parameter
on the dynamics oftreatment response.Figure2a showsthenumber
of differentiated cancer cells as a function of time after the initiation
of therapy. Note that the dedifferentiation parameter c has a strong
affect on the tumor’s response to treatment; in particular, a larger
value of c corresponds to a poorer response to treatment. In
Figure 2b, we investigate the effect of the dedifferentiation rate, c,
on the probability of resistance, R(t), finding that larger values of c
lead to a substantially higher risk of developing resistance.
The dynamics of treatment response without resistance
mutations
Let us now consider specific examples for the treatment
response of a tumor for a fixed level of the dedifferentiation
parameter, c. In the following we investigate the effects of a variety
of hypothetical drugs that target different cells within the
differentiation hierarchy. Note that these scenarios describe
idealized treatments which exert the specified effects onto cancer
cells; these scenarios serve as examples of the dynamics of the
system during drug treatment. Table 1 provides a summary of the
four treatment strategies considered.
First, let us investigate a hypothetical drug that reduces the
production rate of both progenitor and differentiated cells. Treatment
1 inFigure3 providesa numerical example forsuch a situation.The
panels of the figure show the abundance of differentiated cancer
cells over time in response to treatment (Fig. 3a) as well as the
probability of resistance emerging during treatment (Fig. 3b). Note
that this type of treatment leads to a reduction in the number of
cancer progenitors and differentiated cells, but is incapable of
depleting cancer stem cells. Such interventions might reduce
symptoms for a limited time by debulking the tumor. However,
the persistence of cancer stem cells in this scenario prevents tumor
eradication and permits the evolution of acquired resistance, which
renders the response to treatment short-lived.
Figure 1. Schematic representation of the mathematical model. The mathematical model considers three levels of the differentiation
hierarchy of cells: stem cells, progenitors and differentiated cells. These cell types are present in the system as healthy cells (left), drug-sensitive cancer
cells (middle) and drug-resistant cancer cells (right). Stem cells give rise to progenitors which in turn give rise to differentiated cells. Additionally,
cancer progenitors may have the ability to dedifferentiate to stem cells. The rate of dedifferentiation is denoted by c. Drug-sensitive cancer stem cells
produce drug-resistant cancer stem cells at rate u per cell division.
doi:10.1371/journal.pone.0014366.g001
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production of all cancer cell types but still fail to completely
eradicate the cancer cell population. To illustrate this point,
consider a drug that inhibits all three cancer cell types. A drug
that elicits this response is shown as Treatment 2 in Figure 3.
The performance of a drug with these properties is a slight
improvement over the example considered previously; however,
the probability that acquired resistance will evolve is still
substantial since the drug cannot deplete the cancer stem cell
population. This type of drug allows a stable population of cancer
stem cells to remain and continuously repopulate the progenitor
and differentiated cells.
Let us now consider a drug that reduces the growth rate of all
cancer cell types to a larger extent. An example of this type of
therapy is shown as Treatment 3 in Figure 3. A drug eliciting these
effects is capable of eradicating the disease. Furthermore, the
probability of resistance is small since the cancer stem cell
population is driven to extinction and thus, fewer chances for the
emergence of a resistance mutation to arise. Once treatment has
eradicated cancer stem cells, cancer progenitor and differentiated
cells equally go extinct since the latter cell types do not have
(sufficient) self-renewing abilities.
Lastly, let us consider a drug that inhibits cancer stem cells only.
In this setting, the rate of depletion of the total cancer cell
population may be too slow to be considered effective; an example
is shown as Treatment 4 in Figure 3. The advantage of such a drug is
that the chance of drug-resistant tumors is diminished since there
are so few stem cells. However, the tumor burden remains at a
relatively high level for a prolonged period of time because
differentiated cancer cells are unaffected by the drug.
These four treatment strategies represent idealized therapies;
however, their study leads to insights into how heterogeneous tumor
cell populations respond to treatments that affect particular types of
cells, and suggests the most desirable subpopulation to target.
The dynamics of treatment response with resistance
Instead of considering the proportion of patients that develop
resistance, it is also useful to investigate the expected number of
resistant cells present within a patient for a given mutation rate, u.
In the context of our mathematical model, drug-resistant cancer
stem cells initiate their own cellular differentiation hierarchy (Fig. 1
and equation (2)). With this extension of the mathematical model,
we can investigate an additional aspect of treatment: the
propensity of a drug to delay progression due to resistance, i.e.
the onset of a resistance-driven rebound of the cancer cell
population. Figure 4 shows how drugs that target various
parameters of the cancer cell differentiation hierarchy can have
vastly different effects on the duration of successful treatment
before the onset of resistance.
When comparing drugs that affect the birth and death rates of
cancer stem cells, drugs that target the production of cancer stem
cells lead to a longer time during which treatment is effective and
before resistance emerges. This effect can be seen by comparing
panels a and b with panels c and d of Figure 4, and results from the
fact that a reduction in the number of cancer stem cell divisions
leads to fewer opportunities per unit time for resistant cells to arise.
Figure 4 also shows that dedifferentiation can have a very strong
effect on the time until disease progression. In particular, a change
in the order of magnitude of the dedifferentiation rate has
approximately twice the effect as compared to a change in
magnitude of the mutation rate. Lastly, note that an increased net
growth rate of stem cells delays the rebound of the tumor
population. This fact is due to the maintenance of the stem cell
population near its carrying capacity, which prevents resistant cell
populations from arising since we consider density-dependent
growth dynamics.
Let us now compare the efficacy of different treatment protocols
while also taking into consideration the possibility of resistance
(Fig. 5). We investigate two types of treatment: a drug that causes a
decline in the growth rates of all cancer cell types (Fig. 5 a and c),
and a drug that only inhibits progenitor and differentiated cells
(Fig. 5b and d). When comparing the effectiveness of these two
drugs over short time spans (panels a and b), we find that a drug
that inhibits proliferation for all cell types is preferable as
compared to the other type of treatment – i.e., the total cell
number is significantly lower in the former case. However, over
longer time spans (panels c and d) the drug that only inhibits
Figure 2. The effect of dedifferentiation on the abundance of differentiated cancer cells and the probability of resistance. In panel a,
we show the abundance of differentiated cancer cells over time since the initiation of therapy. In panel b, we plot the probability of resistance versus
time. Growth rates during treatment are ~ r ry~0:001, ~ a ay~ay=100 and ~ b by~by=750, and death rates are ~ c ci~di for i=0,1,2. Other parameters are
rx=0.005, ry=0.008, d0=0.004, d1=0.008, d2=0.05, ax=100d1,b x=100d2, ay=2ax, by=2bx, kx=1.2610
6, ky=6 610
7, u=5 610
29, and v=0.1. The
initial condition for the panels is found by simulating system (1) using the pretreatment parameter values and the initial condition x0(0) =10
6, x1(0)
=10
8, x2(0) =10
10, y0(0) =1, and y1(0) =y2(0) =0. We simulate this system until detection time T, i.e., when y2(T) $10
12, and then simulate the
treatment phase by running system (1) with the initial conditions x0(T), x1(T), …, y2(T) and the treatment parameter values.
doi:10.1371/journal.pone.0014366.g002
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the emergence of resistance. This effect results from the density
dependent growth of cancer stem cells; since this drug does not
inhibit the stem cell population, resistant stem cells never become
established due to the density constraint mechanism. Any resistant
stem cells that arise during administration of this treatment will
have suppressed growth since the stem cell population has already
reached its maximum population size. Note that the short time
span (panels a and b) refers to 500 days after the initiation of
therapy, while the long time span (panels c and d) refers to 5000
days since the start of treatment. The drug shown in panels a and
b does significantly decrease the population of stem cells, and
therefore any resistant stem cell that arises will not be inhibited by
the density constraint mechanism and be able to establish a
resistant clone. Hence in the short term, it is preferable to inhibit
cancer stem cells (panels a and b), while during longer periods of
time (panels c and d), this strategy may backfire because it allows
the resistant tumor stem cells to grow.
A reduction of the dedifferentiation rate has a beneficial effect
regardless of the cell type that the drug targets (Fig. 5). However,
note in Figure 6d that the sensitivity of the system to the
dedifferentiation parameter is decreased with increasing progen-
itor birth rate, ay. An increase in the production of progenitor cells
leads to a larger number of those cells, and thus a decrease in the
dedifferentiation rate will need to be enhanced in order to have a
substantial effect on the stem cell population.
Dedifferentiation increases the risk of pre-existing
resistance
In many cases of treatment failure due to the evolution of
acquired resistance, resistant cells are present at the time of
diagnosis. Let us thus discuss such pre-existent resistance and its
effects on the prognosis of cancer patients (Fig. 6). First we study
the probability of developing resistance prior to detection. Fig. 6a
shows that as the dedifferentiation rate increases, the probability of
pre-existing resistance also increases. This effect arises because
there are more opportunities for resistant cancer stem cells to arise
if an increasing fraction of progenitor cells dedifferentiate to
become cancer stem cells, since we consider the contribution
of dedifferentiating progenitor cells to the total risk of resistance in
the stem cell pool. Fig. 6b displays the number of tumor cells as a
function of time after the initiation of therapy under the
assumption that a small number of resistant cells is present at
the time of diagnosis. Note that the time until the resistant
cells cause a disease rebound is strongly dependent on the
dedifferentiation rate – the larger this rate becomes, the more
rapidly the cancer cell population rebounds due to the expansion
of resistant cells. This finding is consistent with the results shown in
Figure 4.
The success of pulsatile therapy depends on the extent
of dedifferentiation
Anti-cancer therapy is often administered in treatment pulses to
limit the toxicity of these agents. The advantage of treatment
pulses is that higher drug concentrations can be reached using
such a strategy as compared to the continuous dosing regimen.
The disadvantage to pulsatile therapy, however, is that during
treatment breaks, the cancer cell population expands exponentially
Table 1. The effect of different hypothetical treatment
strategies on cancer cell populations.
Stem Cells
Progenitor
Cells
Differentiated
Cells
Treatment 1 2 ++
Treatment 2 ++ +
Treatment 3 ++ +
Treatment 4 + 22
Sensitivity to treatment is denoted by ‘+’ and insensitivity by ‘2’.
doi:10.1371/journal.pone.0014366.t001
Figure 3. The effect of different treatment strategies on the abundance of differentiated cancer cells and the probability of
resistance. The figure shows the abundance of differentiated cancer cells, y2, over time since initiation of therapy in panel a and the probability of
resistance, P(t), as a function of time in panel b. We display four different treatment types that affect the cancer cell populations differentially.
Treatment 1 represents a drug that affects only the production of cancer progenitor and differentiated cells, ~ a ay~ay=100 and ~ b by~by=750. Treatment 2
is a drug affecting all cancer cell types while not inhibiting cancer stem cells by a substantial amount,~ r ry~0:005 while ry~0:008, and ~ a ay~ay=100 and
~ b by~by=750. Treatment 3 represents a drug that affects all cancer cell types and has a substantial effect on stem cells, ~ r ry~0:001, ~ a ay~ay=100 and
~ b by~by=750. Treatment 4 is a drug that decreases only the growth rate of cancer stem cells, ~ r ry~0:001. The pre-treatment parameters are identical to
those in Figure 2, and in both panels we set ~ c ci~di for i=0,1,2.
doi:10.1371/journal.pone.0014366.g003
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resistance. So far, the effects of dedifferentiation of progenitor cells
to a stem cell-like state have not been investigated with respect to
pulsed treatment strategies. Our mathematical model is useful for
evaluating the impact of pulsed therapy with regard to recovery of
the cancer stem cell population by dedifferentiation of progenitors.
Figure 7 shows that higher levels of dedifferentiation, i.e. a
larger rate c, lead to larger rebounds of the cancer cell population
during treatment breaks as well as lower levels of cancer cell
depletion during treatment. Hence the possibility of dedifferenti-
ation of cancer progenitors renders otherwise successful therapy
less effective, to the point of being unsuccessful if the capacity of
progenitors for dedifferentiation is sufficiently large. Fig. 7a
demonstrates the effects of treatment with a drug that only
inhibits the production of cancer stem and progenitor cells. This
scenario leads to a drastic difference between situations with
different levels of the dedifferentiation parameter c. Figure 7b
shows the treatment response to a drug that additionally inhibits
the production of differentiated cancer cells. In this situation, the
difference between varying values of c is not as pronounced since
the drug has a substantial effect on differentiated cancer cells.
Discussion
During normal development, differentiation from stem cells to
final products is unidirectional. Some data suggest that oncogenic
mutations lead to loss of the ability for cells to maintain their
differentiated state. In the case of tumor suppressors, their normal
function may therefore be to maintain the unidirectional flow of
differentiation during development. Their inactivation or alter-
ation of certain signaling pathways may result in the loss of
unidirectionality of this process. Dedifferentiation does not
necessarily refer to a scenario in which every cell reverses its
differentiation phenotype. Instead, a small fraction of committed
progenitor cells may acquire stem cell-like characteristics in
response to genetic or environmental changes, and this small cell
Figure 4. The effect of different cancer stem cell treatment strategies on the time until disease progression. The figure shows the time
until the disease burden increases despite continuous therapy versus the birth rate (panels a and b) and death rate (panels c and d) of cancer stem
cells during therapy. The pre-treatment growth parameters are identical to those in Figure 2, and also ~ a ay~ay=100 and ~ b by~by=750, lastly we set
rz~0:007 az~3ay=4 bz~3bz=4. In panel a, we set ~ c ci~di for i=0,1,2, and u=5 610
29. The parameter~ r ry varies along the x-axis and we consider three
different values of c. In panel b, we set ~ c ci~di for i=0,1,2, and c=10
24. The parameter~ r ry varies along the x-axis and we consider three different values
of u. In panel c, we set ~ c ci~di for i=1,2, u=10
27, ~ r ry~ry, vary ~ c c0 along the x-axis and consider three different values of c. In panel d, we set ~ c ci~di for
i=1,2, c=10
24, ~ r ry~ry, vary ~ c c0 along the x-axis and consider three different values of u.
doi:10.1371/journal.pone.0014366.g004
Cancer Stem Cell Plasticity
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the fraction of cells that dedifferentiate per time unit as gamma. In
this paper, we determine the effects of various values of gamma on
the response of tumors to therapy, which specifically targets
either stem cells or non-stem cells. We have studied four
hypothetical treatment strategies (see Table 1 and the results
section) and have also evaluated the effects of dedifferentiation on
the risk of pre-existing therapy and the success of pulsatile
treatment.
We chose to formulate a simple mathematical framework that
only incorporates the essential considerations of cancer stem,
progenitor and differentiated cells. While our mathematical model
can easily be extended to describe more complicated scenarios
such as interactions of cancer cells with the stroma and immune
system, and the generation of tumor cell heterogeneity through
other avenues such as clonal diversification, we have concentrated
on the analysis of the basic model during different treatment
options. This model will be extended in future work to consider
more complex situations in cancer.
The results obtained from this modeling study indicate that the
response of tumors capable of dedifferentiating is qualitatively
different from a scenario in which treatment cannot completely
eradicate the bulk of tumor cells and the remaining cells lead to a
rebound post-therapy. In the latter case, the remaining cells likely
are sensitive to being re-challenged with treatment and therefore,
pulsed therapy has the potential to eradicate the disease. In a
scenario including the potential of dedifferentiation of cells, pulsed
therapy targeting stem cells is incapable of curing the disease, since
the cancer stem cell pool is continuously repopulated by
progenitor cells during treatment breaks. Therefore, the consid-
eration of a dedifferentiation potential of cancer cells is important
for an accurate understanding of anti-cancer therapy.
Figure 5. The effect of different cancer treatment strategies on the number of differentiated cancer cells in the presence of
resistance. Panels a and b display the tumor cell population after 500 days of treatment for two different types of treatment. In panel a we consider
a treatment that can target all types of cells, and in panel b we consider a treatment that only targets progenitor and differentiated cells. Panels c and
d display the tumor cell population after 5000 days of treatment for two different types of treatment. In panel c we consider a treatment that can
target all types of cells, and in panel d we consider a treatment that only targets progenitor and differentiated cells. The pre-treatment growth
parameters are identical to those in Figure 2 and the growth rate of the resistant cells is identical to that in Figure 4. In all four panels we set
u=5 610
29 and we set ~ c ci~di for i=0,1,2. In panels a and c we set ~ a ay~ay=100 and ~ b by~by=750, and vary ~ r ry (i.e., the drug effect on cancer stem cells)
along the horizontal axis. In panels b and d, we set ~ r ry~ry and ~ b by~by=750, and vary ~ a ay (i.e., the drug effect on cancer progenitors) along the
horizontal axis. In panels a and b, the vertical axis corresponds to the number of differentiated cancer cells after 500 days of treatment, including
resistant and sensitive cancer cells. In panels c and d, the vertical axis corresponds to the number of differentiated cancer cells after 5000 days of
treatment, including resistant and sensitive cancer cells.
doi:10.1371/journal.pone.0014366.g005
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14366There has been significant discussion of the effects of tumor
stem cells that are insensitive to anti-cancer therapy. Standard
therapy inhibits proliferating cells of the tumor bulk but the tumors
recur from drug-insensitive stem cells. Because of this, it has been
suggested that a strategy targeting cancer stem cells is required for
curative therapy. However, if non-stem cells can acquire stem cell
properties with a sufficiently high probability but still much lower
than the differentiation rate, then a stem cell-specific treatment
strategy will be futile. The results of our mathematical modeling
studies described in this paper suggest that higher levels of
dedifferentiation substantially reduce the effectiveness of therapy
directed at cancer stem cells. During pulsed treatment strategies,
the possibility of dedifferentiation leads to higher rebounds of the
cancer cell population during treatment breaks as well as lower
levels of cancer cell reduction during treatment pulses. In addition,
we see that increasing the level of dedifferentiation significantly
Figure 6. The relationship between dedifferentiation rate and pre-existing resistance. Panel a considers the probability of pre-existing
resistance versus the dedifferentiation rate c for several mutation rates. We use the same pre-treatment growth rates as in Figure 2 and the same
growth rates for the resistant cells as in Figure 4, and evolve the system until the tumor population hits size 10
12 and then evaluate the probability
of resistance at that time. Panel b plots the response of a tumor population to a drug, assuming that pre-existing resistant population of cells is
present at beginning of treatment. The sensitive cells have the same growth rate as in Figure 2, and the resistant cell have the same growth rates as
in Figure 4.
doi:10.1371/journal.pone.0014366.g006
Figure 7. The effect of the dedifferentiation rate on differentiated cancer cells during pulsatile therapy. The figure shows the dynamics
of differentiated cancer cells in response to a treatment strategy in which the drug is administered for 30 days, followed by a treatment holiday of 30
days during each pulse. Panel a shows the effects of a drug which inhibits cancer stem cell proliferation and their differentiation to progenitors, while
panel b demonstrates the effects of a drug which additionally inhibits the production of differentiated cancer cells from progenitors. Parameters are
~ c ci~di for i=0,1,2, ~ r ry~0:001, ~ a ay~ay=100, and ~ b by~by in (a) and ~ b by~by=750 in (b). For both panels, the off-treatment parameters are identical to
those in Figure 2.
doi:10.1371/journal.pone.0014366.g007
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PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e14366increases the number of stem cell replications and therefore
increases the probability of acquiring a resistance mutation in a
stem cell. In summary, plasticity of the cancer stem cell phenotype
is an important determinant of the effectiveness of therapy, and its
possibility cannot be neglected to gain an accurate understanding
of the treatment response of human tumors.
Acknowledgments
We would like to thank the Michor lab and three anonymous referees for
comments and advice.
Author Contributions
Conceived and designed the experiments: KL EH FM. Performed the
experiments: KL. Analyzed the data: KL FM. Contributed reagents/
materials/analysis tools: KL FM. Wrote the paper: KL EH FM.
References
1. Gupta PB, Chaffer CL, Weinberg RA (2009) Cancer stem cells: mirage or
reality? Nature Medicine 15: 1010–1012.
2. Wang JCY, Lapidot T, Cashman JD, Doedens M, Addy L, et al. (1998) High
level engraftment of NOD/SCID mice by primitive normal and leukemic
hematopoietic cells from patients with chronic myeloid leukemia in chronic
phase. Blood 91: 2406–2414.
3. Hope KJ, Jin LQ, Dick JE (2004) Acute myeloid leukemia originates from a
hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature
Immunology 5: 738–743.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003)
Prospective identification of tumorigenic breast cancer cells. Proceedings of
the National Academy of Sciences of the United States of America 100:
3983–3988.
5. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007)
Identification and expansion of human colon-cancer-initiating cells. Nature 445:
111–115.
6. Wu CL, Wei QX, Utomo V, Nadesan P, Whetstone H, et al. (2007) Side
population cells isolated from mesenchymal neoplasms have tumor initiating
potential. Cancer Research 67: 8216–8222.
7. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, et al. (2007)
Identification of a subpopulation of cells with cancer stem cell properties in head
and neck squamous cell carcinoma. Proceedings of the National Academy of
Sciences of the United States of America 104: 973–978.
8. Li CW, Heidt DG, Dalerba P, Burant CF, Zhang LJ, et al. (2007) Identification
of pancreatic cancer stem cells. Cancer Research 67: 1030–1037.
9. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, et al.
(2008) Identification of cells initiating human melanomas. Nature 451:
345–U311.
10. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. (2008)
Efficient tumour formation by single human melanoma cells. Nature 456:
593–U533.
11. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, et al. (2010) Heterogeneity for
stem cell-related markers according to tumor subtype and histologic stage in
breast cancer. Clin Cancer Res 16: 876–887.
12. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A (2007) Tumor growth need
not be driven by rare cancer stem cells. Science 317: 337–337.
13. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours:
accumulating evidence and unresolved questions. Nature Reviews Cancer 8:
755–768.
14. Pietras K, O A (2010) Hallmarks of cancer: Interactions with the tumor stroma.
Exp Cell Res.
15. Kondo T, Raff M (2000) Oligodendrocyte precursor cells reprogrammed to
become multipotential CNS stem cells. Science 289: 1754–1757.
16. Sharif A, Legendre P, Pre ´vot V, Allet C, Romao L, et al. (2007) Transforming
growth factor alpha promotes sequential conversion of mature astrocytes into
neural progenitors and stem cells. Oncogene 26: 2695–2706.
17. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, et al. (2010)
Perivascular Nitric Oxide Activates Notch Signaling and Promotes Stem-like
Character in PDGF-Induced Glioma Cells. Cell Stem Cell 6: 141–152.
18. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, et al.
(2010) Leukemia-initiating cells from some acute myeloid leukemia patients with
mutated nucleophosmin reside in the CD34- fraction. Blood 115: 1976–1984.
19. Michor F (2008) Mathematical models of cancer stem cells. Journal of Clinical
Oncology 26: 2854–2861.
20. Ganguly R, Puri IK (2006) Mathematical model for the cancer stem cell
hypothesis. Cell Proliferation 39: 3–14.
21. Dingli D, Traulsen A, Pacheco JM (2007) Stochastic dynamics of hematopoietic
tumor stem cells. Cell Cycle 6: 461–466.
22. Turner C, Stinchcombe AR, Kohandel M, Singh S, Sivaloganathan S (2009)
Characterization of brain cancer stem cells: a mathematical approach. Cell
Proliferation 42: 529–540.
23. Haeno H, Levine RL, Gilliland DG, Michor F (2009) A progenitor cell origin of
myeloid malignancies. Proceedings of the National Academy of Sciences of the
United States of America 106: 16616–16621.
24. Sottoriva A, Verhoeff JJ, Borovski T, McWeeney SK, Naumov L, et al. (2010)
Cancer stem cell tumor model reveals invasive morphology and increased
phenotypical heterogeneity. Cancer Res 70: 46–56.
25. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical
resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or
amplification. Science 293: 876–880.
26. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired
resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. Plos Medicine 2: 225–235.
Cancer Stem Cell Plasticity
PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e14366